MedTrace Logo

The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

NCT06819514 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-02-11

No results posted yet for this study

Summary

A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease

Conditions

Interventions

DRUG

EXG110 Injection

EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.

Sponsors & Collaborators

  • Hangzhou Jiayin Biotech Ltd

    lead INDUSTRY

Principal Investigators

  • Zhihong Liu, MD · The General Hospital of Eastern Theater Command

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2028-03-15
Completion
2028-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06819514 on ClinicalTrials.gov